long-acting azacitidine (NEX-18a)
/ Nanexa AB
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 17, 2023
Pharmacokinetics, Tolerability and Safety of NEX-18a
(clinicaltrials.gov)
- P1 | N=2 | Completed | Sponsor: Nanexa AB | Terminated ➔ Completed
Trial completion • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology
April 12, 2022
Pharmacokinetics, Tolerability and Safety of NEX-18a
(clinicaltrials.gov)
- P1 | N=2 | Terminated | Sponsor: Nanexa AB | Trial completion date: Sep 2021 ➔ Feb 2022 | Recruiting ➔ Terminated | Trial primary completion date: Sep 2021 ➔ Feb 2022; The Sponsor plans for a reformulation of NEX-18 before the clinical phase of the project will be resumed
Trial completion date • Trial primary completion date • Trial termination • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology
September 17, 2021
Pharmacokinetics, Tolerability and Safety of NEX-18a
(clinicaltrials.gov)
- P1; N=6; Recruiting; Sponsor: Nanexa AB
Clinical • New P1 trial • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology
1 to 3
Of
3
Go to page
1